Gujarat Themis Biosyn shares jumped over 15% on Friday, 24 April following the announcement of a significant acquisition deal. According to a stock exchange announcement made late Thursday, the company has signed an Asset Purchase Agreement to acquire 13 well-established branded generic products from Sanofi, the French-based parent company of the Sanofi group. The deal involves purchasing 13 anti-tuberculosis (TB) and anti-infective brands that have a strong market presence in over 55 countries across Europe, the Middle East, and Africa, for Euro 158 million, equivalent to ₹1,740 crore, which will be paid in cash upon closing.
The transaction represents a significant strategic move for Gujarat Themis Biosyn, as the deal size is nearly 50% of the current market capitalization of the company, which stands at ₹3,520 crore. The acquisition is anticipated to be finalized by the end of December 2026 and will be financed through an optimal blend of debt and equity. The company expects the deal to enhance earnings per share (EPS), bolstered by profitable sales of branded generics, vertical integration, and improved operational efficiency.
The portfolio in question reported net sales of around Euro 62 million for the fiscal year ending 2025. According to the company announcement, the acquisition will grant instant access to both regulated and semi-regulated markets, allowing the company to expand its global presence. The transaction will not include the transfer of manufacturing facilities or personnel, resulting in a capital-efficient and asset-light expansion for the company.
Gujarat Themis Biosyn share price opened at ₹330.25 on the BSE and touched an intraday high of ₹373.20 with an intraday low of ₹317 per share. As reported by Angel One's Rajesh Bhosale, the stock is witnessing a strong price and volume breakout, gaining over 13% alongside a sharp surge in volumes. He noted that a saucer pattern breakout has emerged, indicating a bullish trend continuation, with prices likely to extend towards the ₹420–430 range on the upside, while ₹340 is expected to act as a strong support level on the downside.
The acquisition is projected to bolster the company's global pharmaceutical platform and increase its footprint in the anti-infective market. According to the company statement, this deal will present a significant chance for forward integration, enabling the company to utilize its current strengths in fermentation-derived intermediates and APIs to bolster the purchased finished dosage formulations portfolio and enhance returns throughout the value chain. The transaction will encompass marketing authorizations, brands, regulatory files, inventory, and associated commercial rights.
